RFA-HL-23-009 - NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)

On This Page: 1

Active NOSIs

Title Notice Number Organization Release
Date		 Expiration
Date		 Activity
Code(s)

Expired NOSIs

Title Notice Number Organization Release
Date		 Expiration
Date		 Activity
Code(s)
RESCINDED - NHLBI Notice of Clarification and Availability of Frequently Asked Questions (FAQs) for RFA-HL-23-008 and RFA-HL-23-009 "NHLBI SBIR Phase IIB Small Market Awards" NOT-HL-23-082 NHLBI Mar 16, 2023 n/a R44
For technical issues E-mail OER Webmaster